EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

A strong case for third-party testing

Fridtjof Lund-Johansen iD

eLife · 14.11.2023 · 12

DOI: 10.7554/elife.93329 ↗

Kurz gefasst

Editorial in der Zeitschrift eLife, online erschienen am 14.11.2023. Verfasst von Fridtjof Lund-Johansen. Beteiligte Einrichtung: Department of Immunology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Antibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A strategy to identify high-quality commercially available antibodies for research reveals extensive use of non-specific antibodies and offers solutions for future large-scale testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntibodiesAntibody Specificity

Stichwörter der Autor:innen

antibodyantibody specificityantibody validationbiochemistrycell biologychemical biologyhumanpolyclonal antibodyrecombinant antibody

Substanzen

Antibodies

Autor:innen und Institutionen

  • Department of Immunology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Fridtjof Lund-Johansen

Zitieren

APA

Lund-Johansen, F. (2023). A strong case for third-party testing. eLife, 12. https://doi.org/10.7554/elife.93329

Vancouver

Lund-Johansen F. A strong case for third-party testing. eLife. 2023;12. doi:10.7554/elife.93329

BibTeX
@article{LundJohansen2023,
  author = {Lund-Johansen, Fridtjof},
  title = {A strong case for third-party testing},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.93329}
}
Kostenlos starten →